Segment disclosures

Company overview

THERAVANCE BIOPHARMA, INC.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

5 dimension combinations 36 retained observations 11 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Collaborative Arrangement Revenue · Single Reportable Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=tbph:CollaborativeArrangementRevenueMember;us-gaap:StatementBusinessSegmentsAxis=tbph:SingleReportableSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3020731000 USD20260811Open filing evidence
2026-01-01 – 2026-06-3038430000 USD20260811Open filing evidence
2025-01-01 – 2025-12-3174964000 USD20260323Open filing evidence
2025-07-01 – 2025-09-3019990000 USD20251112Open filing evidence
2025-01-01 – 2025-09-3054073000 USD20251112Open filing evidence
2025-04-01 – 2025-06-3018695000 USD20260811Open filing evidence
2025-01-01 – 2025-06-3034083000 USD20260811Open filing evidence
2024-01-01 – 2024-12-3164381000 USD20260323Open filing evidence
2024-07-01 – 2024-09-3016868000 USD20251112Open filing evidence
2024-01-01 – 2024-09-3045627000 USD20251112Open filing evidence

Co Promote Agreement · Single Reportable Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=tbph:CoPromoteAgreementMember;us-gaap:StatementBusinessSegmentsAxis=tbph:SingleReportableSegmentMember
PeriodValueUnitFiledEvidence
2025-04-01 – 2025-06-3018695000 USD20250813Open filing evidence
2025-01-01 – 2025-06-3034083000 USD20250813Open filing evidence
2024-04-01 – 2024-06-3014256000 USD20250813Open filing evidence
2024-01-01 – 2024-06-3028759000 USD20250813Open filing evidence

Licensing And Milestone · Single Reportable Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=tbph:LicensingAndMilestoneMember;us-gaap:StatementBusinessSegmentsAxis=tbph:SingleReportableSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-3132500000 USD20260323Open filing evidence
2025-04-01 – 2025-06-307500000 USD20260811Open filing evidence
2025-01-01 – 2025-06-307500000 USD20260811Open filing evidence

License · Single Reportable Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=us-gaap:LicenseMember;us-gaap:StatementBusinessSegmentsAxis=tbph:SingleReportableSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-09-307500000 USD20251112Open filing evidence
2025-04-01 – 2025-06-307500000 USD20250813Open filing evidence
2025-01-01 – 2025-06-307500000 USD20250813Open filing evidence

Single Reportable Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=tbph:SingleReportableSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3020731000 USD20260811Open filing evidence
2026-01-01 – 2026-06-3038430000 USD20260811Open filing evidence
2026-01-01 – 2026-03-3117699000 USD20260507Open filing evidence
2025-01-01 – 2025-12-31107464000 USD20260323Open filing evidence
2025-07-01 – 2025-09-3019990000 USD20251112Open filing evidence
2025-01-01 – 2025-09-3061573000 USD20251112Open filing evidence
2025-04-01 – 2025-06-3026195000 USD20260811Open filing evidence
2025-01-01 – 2025-06-3041583000 USD20260811Open filing evidence
2025-01-01 – 2025-03-3115388000 USD20260507Open filing evidence
2024-01-01 – 2024-12-3164381000 USD20260323Open filing evidence
2024-07-01 – 2024-09-3016868000 USD20251112Open filing evidence
2024-01-01 – 2024-09-3045627000 USD20251112Open filing evidence
2024-04-01 – 2024-06-3014256000 USD20250813Open filing evidence
2024-01-01 – 2024-06-3028759000 USD20250813Open filing evidence
2024-01-01 – 2024-03-3114503000 USD20250512Open filing evidence
2023-01-01 – 2023-12-3157424000 USD20250307Open filing evidence